SELECT PUBLICATIONS

  1. Dhavale DD, Barclay AM, Borcik CG, Basore K, Berthold DA, Gordon IR, Liu J, Milchberg MH, O'Shea JY, Rau MJ, Smith Z, Sen S, Summers B, Smith J, Warmuth OA, Perrin RJ, Perlmutter JS, Chen Q, Fitzpatrick JAJ, Schwieters CD, Tajkhorshid E, Rienstra CM, Kotzbauer PT. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nat Commun. 2024 Mar 29;15(1):2750.

  2. Sharma A, Dhavale DD, Kotzbauer PT, Weihl CC. VCP Inhibition Augments NLRP3 Inflammasome Activation. Inflammation. 2024 Apr 2.

  3. Kim HY, Chia WK, Hsieh CJ, Saturnino Guarino D, Graham TJA, Lengyel-Zhand Z, Schneider M, Tomita C, Lougee MG, Kim HJ, Pagar VV, Lee H, Hou C, Garcia BA, Petersson EJ, O'Shea J, Kotzbauer PT, Mathis CA, Lee VM, Luk KC, Mach RH. A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy. J Med Chem. 2023 Sep 14;66(17):12185-12202.

  4. Miller RL, Dhavale DD, O'Shea JY, Andruska KM, Liu J, Franklin EE, Buddhala C, Loftin SK, Cirrito JR, Perrin RJ, Cairns NJ, Campbell MC, Perlmutter JS, Kotzbauer PT. Quantifying regional α -synuclein, amyloid β, and tau accumulation in lewy body dementia. Ann Clin Transl Neurol. 2022 Feb;9(2):106-121.

  5. Myers PS, O'Donnell JL, Jackson JJ, Lessov-Schlaggar CN, Miller RL, Foster ER, Cruchaga C, Benitez BA, Kotzbauer PT, Perlmutter JS, Campbell MC. Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. Neurology. 2022 Jul 5;99(1):e66-e76.

  6. Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, Holtzman DM. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 2020 Feb 5;12(529):eaay3069.

  7. French RL, Grese ZR, Aligireddy H, Dhavale DD, Reeb AN, Kedia N, Kotzbauer PT, Bieschke J, Ayala YM. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem. 2019 Apr 26;294(17):6696-6709.

  8. Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics. J Biol Chem. 2019 Jan 18;294(3):1045-1058.

  9. Yue X, Dhavale DD, Li J, Luo Z, Liu J, Yang H, Mach RH, Kotzbauer PT, Tu Z. Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation. Bioorg Med Chem Lett. 2018 Apr 1;28(6):1011-1019.

  10. Dhavale DD, Tsai C, Bagchi DP, Engel LA, Sarezky J, Kotzbauer PT. A sensitive assay reveals structural requirements for α-synuclein fibril growth. J Biol Chem. 2017 Jun 2;292(22):9034-9050.

  11. Sundaram GS, Dhavale DD, Prior JL, Yan P, Cirrito J, Rath NP, Laforest R, Cairns NJ, Lee JM, Kotzbauer PT, Sharma V. Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease. Sci Rep. 2016 Nov 2;6:35636.

  12. Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, Kotzbauer PT. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2015 Oct;2(10):949-59.

  13. Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, Xu J, Dhavale D, Bagchi DP, d'Avignon A, Shakerdge NB, Bacskai BJ, Tu Z, Kotzbauer PT, Mach RH. Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils. J Med Chem. 2015 Aug 13;58(15):6002-17.

  14. Campbell MC, Koller JM, Snyder AZ, Buddhala C, Kotzbauer PT, Perlmutter JS. CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology. 2015 Jun 16;84(24):2413-21.

  15. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging. 2015 Jan;36(1):476-84.

  16. Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One. 2013;8(2):e55031.

  17. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol. 2012 Oct;69(10):1326-31.

  18. Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. Synthesis and in vitro evaluation of α-synuclein ligands. Bioorg Med Chem. 2012 Aug 1;20(15):4625-34.

  19. Engel LA, Jing Z, O'Brien DE, Sun M, Kotzbauer PT. Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One. 2010 Sep 23;5(9):e12897.

  20. Kotzbauer PT, Holtzman DM. Expectations and challenges in the therapeutic use of neurotrophic factors. Ann Neurol. 2006 Mar;59(3):444-7.

  21. Liang TW, Truax AC, Trojanowski JQ, Lee VM, Stern MB, Kotzbauer PT. Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor- predominant neurodegeneration with brain iron accumulation. Mov Disord. 2006 May;21(5):718-22.

  22. Malik I, Turk J, Mancuso DJ, Montier L, Wohltmann M, Wozniak DF, Schmidt RE, Gross RW, Kotzbauer PT. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol. 2008 Feb;172(2):406-16.

  1. Dhavale DD, Barclay AM, Borcik CG, Basore K, Berthold DA, Gordon IR, Liu J, Milchberg MH, O’Shea JY, Rau MJ, Smith Z, Sen S, Summers B, Smith J, Warmuth OA, Perrin RJ, Perlmutter JS, Chen Q, Fitzpatrick JAJ, Schwieters CD, Tajkhorshid E, Rientra CM, & Kotzbauer PT. (2024). Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. Nature Communications. 15, 2750.

  2. Miller, R.L., Dhavale, D.D., O’Shea, J.Y., Andruska, K.M., Liu, J., Franklin, E.E., Buddhala, C., Loftin, S.K., Cirrito, J.R., Perrin, R.J., Cairns, N.J., Campbell, M.C., Perlmutter, J.S. and Kotzbauer, P.T. (2022), Quantifying regional α -synuclein, amyloid β, and tau accumulation in lewy body dementia. Ann Clin Transl Neurol, 9: 106-121.

  3. Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, & Holtzman DM. (2020). APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 12(529): eaay3069.

  4. Campbell MC, Jackson JJ, Koller JM, Snyder AZ, Kotzbauer PT, & Perlmutter JS. (2020). Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease. Neurol. 94(7): e718-e728.

  5. Barthélemy NR, Liu H, Lu W, Kotzbauer PT, Bateman RJ, & Lucey BP. (2020). Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid. Ann of Neurol. 87(5): 700-709.

  6. French RL, Grese ZR, Aligireddy H, Dhavale DD, Reeb AN, Kedia N, Kotzbauer PT, Bieschke J, & Ayala YM. (2019). Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem. 294(17): 6696-6709.

  7. Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI. (2019).
    Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics. J Biol Chem. 294(3): 1045-1048.

  8. Hsieh CJ, Ferrie JJ, Xu K, Lee I, Graham TJA, Tu Z, Yu J, Dhavale D, Kotzbauer P, Petersson EJ, & Mach RH. (2018). Alpha Synuclein Fibrils Contain Multiple Binding Sites for Small Molecules. ACS Chem Neurosci. 9(11): 2521-2527.

  9. Hsieh CJ, Xu K, Lee I, Graham TJA, Tu Z, Dhavale D, Kotzbauer P, & Mach RH. (2018). Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro. ACS Omega. 3(4): 4486-4493.

  10. Yue X, Dhavale DD, Li J, Luo Z, Liu J, Yang H, Mach RH, Kotzbauer PT, Tu Z. (2018). Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation. Bioorg Med Chem Lett. 28(6): 1011-1019.

  11. Barclay AM, Dhavale DD, Courtney JM, Kotzbauer PT, Rienstra CM. (2018). Resonance assignments of an α-synuclein fibril prepared in Tris buffer at moderate ionic strength. Biomol NMR Assign. 12(1): 195-199.

  12. Dhavale DD, Tsai C, Bagchi DP, Engel LA, Sarezky J, Kotzbauer PT. (2017). A sensitive assay reveals structural requirements for α-synuclein fibril growth. J Biol Chem. 292:9034-9050.

  13. Kotzbauer PT, Tu Zhude, & Mach RH. (2017). Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. Clinical and Translational Imaging. 5: 3-14.

  14. Sundaram GS, Dhavale DD, Prior JL, Yan P, Cirrito J, Rath NP, Laforest R, Cairns NJ, Lee JM, Kotzbauer PT, Sharma V. (2016). Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease. Sci Rep. 6:35636.

  15. Campbell MC, Koller JM, Snyder AZ, Buddhala C, Kotzbauer PT, Perlmutter JS. (2015). CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology. 84:2413-2421.

  16. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. (2015). Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging. 36:476-484.

  17. Chuang DY, Simonyi A, Kotzbauer PT, Gu Z, Sun GY. (2015). Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway. J Neuroinflammation. 12:199.

  18. Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, Xu J, Dhavale D, Bagchi DP, d'Avignon A, Shakerdge NB, Bacskai BJ, Tu Z, Kotzbauer PT, Mach RH. (2015). Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils. J Med Chem. 58:6002-6017.

  19. Bagchi DP & Kotzbauer PT. (2015). Mouse Models of Neuroaxonal Dystrophy Caused by PLA2G6 Gene Mutations. Movement Disorders: Genetics and Models: Second Edition. Elsevier Inc., p. 923-935.

  20. Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, Kotzbauer PT. (2015). Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2:949-959.

  21. Sundaram GS, Dhavale D, Prior JL, Sivapackiam J, Laforest R, Kotzbauer P, Sharma V. (2015). Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer's disease. EJNMMI Res. 5:112.

  22. Zhang X, Jin H, Padakanti PK, Li J, Yang H, Fan J, Mach RH, Kotzbauer P, Tu Z. (2014). Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein. Appl Sci (Basel). 4:66-78.

  23. Armstrong RA, Kotzbauer PT, Perlmutter JS, Campbell MC, Hurth KM, Schmidt RE, Cairns NJ. (2014). A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. J Neural Transm (Vienna). 121:171-181.

  24. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI. (2013). Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 110:E3138-3147.

  25. Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. (2013). Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One. 8:E55031.

  26. Racette BA, Criswell SR, Lundin JI, Hobson A, Seixas N, Kotzbauer PT, Evanoff BA, Perlmutter JS, Zhang J, Sheppard L, Checkoway H. (2012). Increased risk of parkinsonism associated with welding exposure. Neurotoxicology. 33:1356-1361.

  27. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS. (2012). Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol. 69:1326-1331.

  28. Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. (2012). Synthesis and in vitro evaluation of α-synuclein ligands. Bioorg Med Chem. 20:4625-4634.

  29. Engel LA, Jing Z, O'Brien DE, Sun M, Kotzbauer PT. (2010). Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One. 5:E12897.

  30. Li M, Husic N, Lin Y, Christensen H, Malik I, McIver S, LaPash Daniels CM, Harris DA, Kotzbauer PT, Goldberg MP, Snider BJ. (2010). Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods. 189:56-64.

  31. Mancuso DJ, Kotzbauer P, Wozniak DF, Sims HF, Jenkins CM, Guan S, Han X, Yang K, Sun G, Malik I, Conyers S, Green KG, Schmidt RE, Gross RW. (2009). Genetic ablation of calcium-independent phospholipase A2{gamma} leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction. J Biol Chem. 284:35632-35644.

  32. Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N, Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A, Levinson B, Dias C, Barbot C, Carrilho I, Santos M, Malik I, Gitschier J, Hayflick SJ. (2008). Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology. 71:1402-1409.

  33. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. (2008). Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 28:7687-7698.

  34. Malik I, Turk J, Mancuso DJ, Montier L, Wohltmann M, Wozniak DF, Schmidt RE, Gross RW, Kotzbauer PT. (2008). Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol. 172:406-416.

  35. Kotzbauer PT, Holtzman DM. (2006). Expectations and challenges in the therapeutic use of neurotrophic factors. Ann Neurol. 59:444-447.

  36. Liang TW, Truax AC, Trojanowski JQ, Lee VM, Stern MB, Kotzbauer PT. (2006). Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor-predominant neurodegeneration with brain iron accumulation. Mov Disord. 21:718-722.

  37. Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM. (2005). Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci. 25:689-698.

  38. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM. (2004). Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 187:279-288.

  39. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 300:636-640.